The Supreme Court ruled that human DNA isolated from a chromosome cannot be patented as it is a product of nature. The decision distinguishes between natural phenomena and synthetic DNA, which is patentable. Myriad Genetics' patents on BRCA1 and BRCA2 genes were challenged, impacting testing and research. The ruling is expected to lower test costs and promote innovation.
documents/EFTA01092332.pdf
{}